Company intelligence / Profile preview
Vaxent
Memphis, Tennessee, United States
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Vaxent's lead multivalent subunit vaccine against group A streptococcus (StreptAnova) entered Phase 1 trials in 2015, assessing safety and immunogenicity in healthy adults; no further public clinical results are available as of 2025.
- Therapeutic areas
- Infectious DiseasesRheumatologyCardiovascular
- Modalities
- VaccineProteinPeptide vaccine
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Pan-Provincial Vaccine Enterprise (PREVENT)University of Tennessee Health Science CenterMemphis Bioworks Foundation Incubator
Beyond the preview
Go deeper on Vaxent.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vaxent.